Ibuprofen enhances the anticancer activity of cisplatin in lung cancer cells by inhibiting the heat shock protein 70

H Endo¹,², M Yano*,¹,², Y Okumura¹ and H Kido¹

Hsp70 is often overexpressed in cancer cells, and the selective cellular survival advantage that it confers may contribute to the process of tumour formation. Thus, the pharmacological manipulation of Hsp70 levels in cancer cells may be an effective means of preventing the progression of tumours. We found that the downregulation of Hsp70 by ibuprofen in vitro enhances the antitumoural activity of cisplatin in lung cancer. Ibuprofen prominently suppressed the expression of Hsp70 in A549 cells derived from lung adenocarcinoma and sensitized them to cisplatin in association with an increase in the mitochondrial apoptotic cascade, whereas ibuprofen alone did not induce cell death. The cisplatin-dependent events occurring up- and downstream of mitochondrial disruption were accelerated by treatment with ibuprofen. The increase in cisplatin-induced apoptosis caused by the depletion of Hsp70 by RNA interference is evidence that the increased apoptosis by ibuprofen is mediated by its effect on Hsp70. Our observations indicate that the suppression of Hsp70 by ibuprofen mediates the sensitivity to cisplatin by enhancing apoptosis at several stages of the mitochondrial cascade. Ibuprofen, therefore, is a potential therapeutic agent that might allow lowering the doses of cisplatin and limiting the many challenge associated with its toxicity and development of drug resistance.

Cell Death and Disease (2014) 5, e1027; doi:10.1038/cddis.2013.550; published online 30 January 2014

Subject Category: Cancer

The human Hsp70 family includes ≥8 highly homologous members that differ from each other by their intracellular localization and expression patterns. Among them, the major stress-inducible Hsp70 (also called Hsp72) has an essential role in cell survival under stressful conditions. Compared with its normal counterpart, Hsp70 is often overexpressed in various cancer cells and is suspected to contribute to the development of tumours. Indeed, the expression of Hsp70 in certain cancer types has been correlated with poor prognosis and resistance to chemotherapy.

Tumour cells often express several proteins that, when abnormally elevated, render the tumour resistant to apoptosis. Previous studies have confirmed not only that Hsp70 is cytoprotective, but also that it interferes effectively with cell death induced by a wide variety of stimuli, including several cancer-related stresses. Hsp70 is a potent inhibitor of the stress-activated kinase pathway, and apparently blocks apoptotic signals via interactions with JNK, Ask1 and SEK1. Hsp70 is also a negative regulator of the mitochondrial pathway of apoptosis. Much of the focus on the antia apoptotic function of Hsp70 has been on events that occur after the disruption of the mitochondria. Hsp70 prevents the recruitment of procaspase-9 to the apoptosome, and its functional complex formation by direct interaction with apoptotic protease-activating factor 1 (Apaf-1). Furthermore, Hsp70 inhibits the activation of caspase-3 and the cleavage of caspase-3 targets, such as ICAD and GATA-1. On the other hand, recent studies have reported that Hsp70 can prevent apoptosis upstream of the mitochondria, by inhibiting events, which, ultimately, permeabilize the mitochondrial outer membrane, such as the activation of Bax.

As a result of the inhibition by Hsp70 of the apoptosis induced by several anticancer drugs, as well as by other stimuli, we hypothesized that cancer cells would be sensitized to the induction of apoptosis by the neutralization of Hsp70. Hsp70 has been, indeed, targeted with pharmaceuticals, such as triptolide, quercetin and KNK437, which downregulate its expression. Although they have prevented the progression of various cancer cells in vitro and in vivo, the optimal clinical use of these small Hsp70 inhibitors singly or combined with other chemotherapeutics remains a challenge. Our overall objective was to pharmacologically control the levels of Hsp70, and increase the effectiveness of anticancer drugs.

Several experimental and epidemiologic studies and clinical trials have observed a powerful chemopreventive activity exerted by nonsteroidal anti-inflammatory drugs (NSAIDs). The anti-carcinogenic properties of NSAID...
have been attributed to their inhibition of cyclooxygenase (COX) enzymes. However, much higher doses of NSAID are needed to obtain an antitumoural effect than to inhibit COX, suggesting that they also act via COX-independent mechanisms. On the other hand, NSAIDs, such as aspirin, salicylate and sulindac sulphide, inhibit the proliferation of cells and induce apoptosis in various cancer cell lines, which is considered an important component of their antitumoural activity, and increased sensitization of cancer cells to anticancer drugs. There is current interest in the ability of NSAID to directly lower the levels of antiapoptotic molecules, such as the Bcl-2 family and 14-3-3 protein, which inhibits the intrinsic mitochondria-dependent apoptosis in various cancer cells. Therefore, the NSAID-induced dysfunction of antiapoptotic proteins prompted us to examine whether other antiapoptotic molecules, including Hsp70, might also be targets in the prevention of tumour progression by NSAID. In this study, we show that ibuprofen is a potent inhibitor of Hsp70, which significantly suppresses its expression by depleting heat shock factor 1 (HSF1) in lung adenocarcinoma-derived A549 cells. The downregulation of Hsp70 by ibuprofen sensitized the cells to cisplatin, which was associated with the enhancement of cisplatin-induced apoptotic signalling. Ibuprofen did not only facilitate postmitochondrial events, including the activation of cisplatin-induced caspase-9, but also the activation of Bax, causing the release of cytochrome c. Besides the demonstration of a similar increase in the sensitivity of A549 cells to cisplatin conferred by Hsp70 knockdown and ibuprofen, these observations indicate that ibuprofen accelerates cisplatin-mediated apoptosis at multiple steps of the mitochondrial apoptotic pathway via the inhibition of Hsp70. We conclude that ibuprofen is a potential chemotherapeutic agent, which might enable (a) the use of lower, less toxic doses of cisplatin and (b) the design of a new combination treatment of lung cancer.

Results

Ibuprofen suppresses the expression of Hsp70 in lung adenocarcinoma cells. To define the role of Hsp70 in promoting the formation of tumours, we first examined its expression in human lung cancer cell lines. Compared with BEAS-2B, a human, non-malignant, bronchial epithelial cell line, the expression levels of Hsp70 in lung cancer cells, such as A549 and H358 adenocarcinoma, were notably higher (Figure 1a). As in previous studies, which showed an increased expression of Hsp70 in various types of human cancers, including breast, pancreas and colon, we found that Hsp70 is also dysregulated in lung cancer cells. In this study, we screened conventional NSAID in search of a new pharmacologic inhibitor, which neutralizes Hsp70, as they induce apoptosis in cancer cells by selectively downregulating antiapoptotic proteins. The expression of Hsp70 after the exposure of A549 cells to various NSAID in non-toxic concentrations, was analyzed by immunoblot. Ibuprofen, in a 400 μM concentration, decreased the expression of Hsp70 by 23% in comparison with untreated cells, whereas other NSAID had no effect (Table 1). Figure 1b shows the decrease in Hsp70 protein and mRNA levels in A549 cells, after treatment with various concentrations of ibuprofen, versus no apparent decreases in Hsc70 and Actin. Ibuprofen also decreased the expression of Hsp70 in H358, a human lung adenocarcinoma cell line, in a dose-dependent manner (Figure 1c). These results suggest that ibuprofen decreases the expression of Hsp70 in various lung cancer cell lines.

Ibuprofen enhances the apoptosis induced by cisplatin by suppressing Hsp70. As ibuprofen prominently inhibited the expression of Hsp70, we next examined its effect on the proliferation of cancer cells. We observed no significant change in the viability of A549 and H358 cells after the

Figure 1  Ibuprofen suppresses the expression of Hsp70 in lung adenocarcinoma cells. (a) Upregulation of Hsp70 in lung cancer cell lines. Each cell extract was separated by SDS-PAGE and immunoblotted with an anti-Hsp70 or actin antibody (upper panel). The quantity of each protein was estimated by densitometric analysis using Scion Image (Scion, Frederick, MD, USA). The Hsp70/actin ratios are shown in the lower panel. (b) Effect of ibuprofen on the expression of Hsp70 protein and mRNA in A549 cells. Top: expression of Hsp70 and Hsc70 proteins in A549 cells treated with ibuprofen at the specified concentrations for 48 h, examined as described in (a) (left panel). Bottom: densitometric analysis of each protein level in arbitrary unit (arb-u). The alternation of each mRNA expression after ibuprofen treatment was analyzed by semiquantitative RT-PCR (top right panel). These results are representative of three separate experiments. (c) Effect of ibuprofen on the expression of Hsp70 protein in H358 cells. Expression of Hsp70 proteins in H358 cells treated with ibuprofen at the specified concentrations for 48 h (upper panel). The quantity of each protein was estimated by densitometric analysis (lower panel).
Ibuprofen increases the activation of Bax induced by cisplatin. The translocation of the pro-apoptotic protein Bax...
to the mitochondria is closely associated with the apoptosis induced by cisplatin. To explore the mechanisms by which ibuprofen promotes the apoptosis mediated by mitochondria in response to cisplatin, we examined whether it was due to its ability to stimulate the translocation of Bax by cisplatin. We first monitored conformational changes in Bax as indicators of its activation. Western blot analysis of the immunoprecipitates with a conformation specific anti-Bax (6A7) antibody, which only recognizes the active form, revealed the presence of active Bax in A549 cells treated with cisplatin (Figure 5a, lane 4), although not in untreated cells (Figure 5a, lanes 1 and 2). Further exposure of the
cisplatin-treated cells to ibuprofen caused a 1.5-fold increase in active Bax, compared with incubation with cisplatin alone (Figure 5a, lane 3). When we analyzed the effects conferred by ibuprofen on the translocation of Bax to mitochondria in cisplatin-treated cells, we observed an approximately 1.3-fold increase in the amount of translocated Bax (Figure 5b). To exclude an effect of ibuprofen unrelated to the inhibition of Hsp70, we performed RNAi for a selective knock-down of Hsp70, and we studied its effects on the activation of Bax. Consistent with the earlier data presented for ibuprofen, the depletion of Hsp70 increased the activation of Bax in cisplatin-treated cells, although its extent was greater with Hsp70 RNAi than with ibuprofen (Figure 5c). These observations confirmed that (a) ibuprofen promotes the activation of Bax dependent on cisplatin and its translocation to the mitochondria in A549 cells and (b) its mechanism of action is mediated by the inhibition of Hsp70.

Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria. Ibuprofen facilitates events occurring upstream and downstream of mitochondrial disruption in cisplatin-mediated apoptosis. Previous studies have shown that Hsp70 can inhibit apoptosis by acting downstream of the mitochondria.

Figure 3 Ibuprofen inhibits the expression of Hsp70 by transcriptional inactivation. (a) ChIP assay for the association of HSF-1 with Hsp70 gene in A549 cells treated with or without ibuprofen. The DNA in the product immunoprecipitated by anti-HSF-1 or non-immune IgG was followed by PCR with a primer specific to the Hsp70 promoter. The immunoprecipitates with antibody against HSF-1 were confirmed by immunoblotting (bottom left). The actin signal is a control of DNA input (bottom right). (b) Effect of ibuprofen on the expression of HSF-1. Cell extracts from A549 cells with ibuprofen for 48 h were separated by SDS-PAGE and immunoblotted with a HSF-1-specific antibody (upper panel). The quantity of each protein was estimated by densitometric analysis (middle panel). The data are representative of three separate experiments. The effect of ibuprofen on the mRNA level of HSF-1 was confirmed by RT-PCR (lower panel). (c) HSF1-mediated inhibition of Hsp70 expression. A549 cells were treated with 10 nM siRNAs against HSF-1 or non-code siRNA. The HSF-1 silencing efficiency and its effect on the expression of Hsp70 were examined by immunoblotting, using appropriate antibodies. Three separate siRNAs oligo against HSF-1 were used for its knock-down. The results shown are representative of three separate experiments.

Figure 2 Ibuprofen increased the antitumoural activity of cisplatin by suppressing Hsp70. (a) The viability of A549 (upper panel) and H358 (lower panel) cells treated with ibuprofen for 48 h was analyzed by MTT assay. The value is represented as the percentage of cell viability without ibuprofen, set at 100%. (b) Synergistic effect of ibuprofen on cisplatin-induced apoptosis in A549 (upper panel) or H358 (lower panel) cells. The cells were treated with the specified concentrations of cisplatin in absence or presence of 400 μM ibuprofen for 48 h, and the cell viability was assessed by MTT assay. The results are shown as means ± S.D. from triplicated experiments. The results shown are representative of three separate experiments. *P<0.05; **P<0.01 (by Student’s t-test). (c) Time course of cisplatin-mediated cell death with ibuprofen. A549 cells were treated with 400 μM ibuprofen alone or A549 cells with 10 μM cisplatin were cultured in absence or presence of 400 μM ibuprofen, and the cell viability was analyzed by TUNEL staining. The results shown are means ± S.D. **P<0.01 (by Student’s t-test). (d) The silencing efficiency of Hsp70 determined by immunoblotting. (e) Effect of Hsp70 RNAi on the cisplatin-mediated death of A549 cells. The cells exposed to siRNA targeting Hsp70 or control siRNA were treated with 10 μM cisplatin for 48 h, and MTT assay was used to determine the cell viability. Data are presented as means ± S.D. from triplicated experiments. The results shown are representative of three separate experiments. *P<0.05; **P<0.01 (by Student’s t-test). (f) Cytofluorimetric dot plot analysis of the CF488A-Annexin V versus propidium iodide (PI) staining performed in 10 μM cisplatin-treated or -untreated A549 cells in absence or presence of 400 μM ibuprofen for 48 h. A representative experiment out of three performed with similar results is shown. (g) Effect of cisplatin on the expression of Hsp70. The data are representative of three separate experiments.
It is noteworthy that treatment with ibuprofen increased $>4$-fold the amount of active caspase-9 in cells treated with cisplatin, compared with cells incubated with cisplatin alone (Figure 6a, lane 4). As, as reported earlier, the highest increases in the activation of Bax and release of cytochrome c by ibuprofen were $<2$-fold, these observations suggest that ibuprofen also facilitates the post mitochondrial process taking place between the release of cytochrome c and the activation of caspase-9. To verify that this is a specific effect, we studied the effect of Hsp70 knock-down on the activation of caspase-9 mediated by cisplatin. The caspase-9 activity in cells depleted of Hsp70 with cisplatin was fourfold greater than in control (scrambled) siRNA-treated cells (Figure 6b). We obtained similar results when we measured the activity of caspase-9 in cells treated with ibuprofen (Figure 6c) or siRNA against Hsp70 (Figure 6d) by a fluorometric assay using a synthetic substrate.

Table 2 Effects of nonsteroidal anti-inflammatory drugs on the expression of HSF-1 in A549 cells

| NSAIDs   | HSF-1 expression (%) |
|----------|----------------------|
| Ibuprofen (400 μM) | 16.2 ± 3.9          |
| Aspirin (2500 μM)   | 93.5 ± 2.9           |
| Diclofenac (200 μM) | 96.7 ± 6.6           |
| Sulindac (15 μM)    | 99.8 ± 3.6           |
| Piroxicam (60 μM)   | 96.3 ± 4.7           |
| Indomethacin (10 μM)| 98.1 ± 1.6           |
| Mefenamic acid (25 μM)| 98.5 ± 1.1      |

Values are shown as means ± S.D. The expression of HSF-1 was measured by immunoblotting with anti-HSF-1 antibody. The quantity of HSF-1 protein was estimated by densitometric analysis using Scion Image. The values in parentheses are the highest non-toxic concentrations (approximately 90% viability) used for each of the NSAID on the A549 cells for 48h.

Figure 4 Ibuprofen exposure enhanced the cisplatin-dependent mitochondrial membrane depolarization and cytochrome c release. (a) A549 cells were treated for 48 h with 10 μM cisplatin, 400 μM ibuprofen, or both, and subjected to JC-1 staining to study the changes in mitochondrial membrane potential. The percentages indicate the green fluorescence intensity of JC-1 measuring with FACSCalibur. A representative experiment out of three performed with similar results is shown. (b) A549 cells, treated as described earlier, were fractionated into cytosol, and the release of cytochrome c was analyzed by western blot, using anti-cytochrome c antibody. The expression of Erk was monitored as an internal control of cytosol protein. The quantity of each protein was estimated by densitometric analysis. The results are means of three separate experiments from cells in different cultures.

Figure 5 The downregulation of Hsp70 increased the cisplatin-mediated activation of Bax and its translocation to the mitochondria. (a) Detection of active Bax. A549 cells were treated with cisplatin (10 μM) and/or ibuprofen (400 μM) for 48h. Active Bax was immunoprecipitated with an active conformation-specific monoclonal antibody and revealed by immunoblotting with an anti-Bax polyclonal antibody. The quantity of active Bax was estimated by densitometric analysis. (b) A549 cells, treated as described earlier, were lysed and fractionated by differential centrifugation to separate the mitochondria from the cytosol. The translocation of Bax to the mitochondria was visualized by the immunoblot of mitochondrial fractions, using an anti-Bax antibody. VDAC-1 was used as a loading control to ensure the use of equal amounts of mitochondria. (c) A decrease in Hsp70 by RNAi promoted cisplatin-dependent activation of Bax. A549 cells treated with Hsp70 or control siRNA were incubated in presence or absence of cisplatin; each cell extract was immunoprecipitated with an anti-active Bax antibody, followed by immunoblotting with anti-Bax antibody. The data are representative of three separate experiments.
Overall, these observations confirmed unambiguously that ibuprofen intensified the apoptosis induced by cisplatin by its effects on the events occurring downstream of the mitochondria, by inhibiting Hsp70, although whether it stimulated the formation of apoptosome (essential for the recruitment of procaspase-9) remains to be determined.

We conclude that ibuprofen promotes the apoptosis induced by cisplatin at multiple stages of the mitochondrial cascade, by attenuating the expression of Hsp70 in A549 cells.

Discussion

We found that, compared with non-malignant bronchial epithelial cells, human lung cancer cells overexpressed Hsp70. This is an important observation, as targeting the expression or function of Hsp70 has been suggested as an effective treatment strategy in several cancers, based on the hypothesis that higher levels of Hsp70 protect against cell death and increase the survival rate against modalities used in chemotherapy.\(^1\) In fact, it is well documented that the expression of Hsp70 is significantly increased in cancer tissues and/or serums obtained from patients with non-small cell lung cancer (NSCLC)\(^{34-36}\) and its overexpression correlates with poor prognosis in NSCLC.\(^{36}\) Several reports have indicated that functionally related small molecules that inhibit Hsp70 decrease the viability of colo-rectal or pancreatic cancer cells by promoting apoptosis via the downregulation of Hsp70, and may be a promising new class of cancer chemotherapeutics.\(^{19,21,22}\) We showed that ibuprofen, a relatively non-toxic and widely used NSAID, significantly decreased the expression of Hsp70 in lung adenocarcinoma cell lines. We also clearly demonstrated that the inhibitory mechanisms of ibuprofen on Hsp70 are due to a decrease in HSF1 expression. Although the fundamental mechanism behind the reduction in HSF-1 expression is unknown, a previous study has indicated that the nuclear factor 1 family member NFIX, which codes for site-specific DNA-binding proteins known to have multiple roles in replication, signal transduction and transcription, exerts a transcriptional repressive effect on the expression of HSF1 in cancer cells.\(^{39}\) Whether NFIX is, indeed, involved in the inhibition of HSF1 expression evoked by ibuprofen is applicable in further studies. To the best of our knowledge, this is the first study of the inhibitory effects of NSAID on the cellular expression of Hsp70. In addition, we showed that ibuprofen does not influence the cell viability without additional stimuli, unlike its

Figure 6  Synergistic effect of Hsp70 suppression on the cisplatin-mediated activation of caspase-9. (a) A549 cells were treated with cisplatin and/or ibuprofen, and cell extracts were immunoblotted with active caspase-9 antibody. The lower panel shows the measurement of each caspase-9. (b) A549 cells exposed to siRNA targeting Hsp70 or control siRNA were incubated with or without cisplatin, and the active caspase-9 was detected by western blot using an anti-caspase-9 antibody. The quantity of each protein was estimated by densitometric analysis (lower panels). (c and d) Assay for enzymatic activity of caspase-9, using a fluorogenic substrate. (c) After the incubation of the A549 cells with cisplatin (10 \(\mu\)M) and/or ibuprofen (400 \(\mu\)M), the caspase-9 activity of each cell extract was measured as described in Materials and methods section. (d) A549 cells transfected with Hsp70 siRNA or control siRNA were exposed to cisplatin for 48 h. The caspase-9 activity was then assessed, using an enzymatic assay as described earlier. The value of caspase-9 activity was presented relative to the activity in untreated cells, set at 1.0. The data represent mean values of three separate experiments. Significances were determined by Student’s t-test (*P<0.05)
maximal effect on the expression of Hsp70. The lack of inhibitory efficacy of ibuprofen against tumours is consistent with a previous study, which showed that low-dose ibuprofen did not induce apoptosis in mouse and human colorectal cancer cell lines.\textsuperscript{42} Similar observations were made following RNAi of Hsp70, suggesting that the attenuation of Hsp70 \textit{per se} is insufficient to cause the death of A549, and perhaps other cells. It has been shown that the knockdown of Hsp70 has no effect on the viability of several cancer cell lines, although sensitized them to anticancer drugs.\textsuperscript{40,41} Therefore, the therapeutic potential of ibuprofen combined with chemotherapeutic agents needs to be explored.

Cisplatin is one of the most effective chemotherapeutic drugs against NSCLCs.\textsuperscript{42} It is noteworthy that damage to chemotherapeutic agents needs to be explored, although sensitized them to anticancer drugs.\textsuperscript{40,41} Therefore, even under \textit{in vitro} activation of caspase by the addition of cytochrome c and dATP.\textsuperscript{44} Furthermore, we were unable to identify a new target for Hsp70 in the process of caspase-9 activation, indicating that its inhibitory activity is attributable to another indirect effect, instead of a direct one as previously reported. Altogether, the data presented here are the first evidence of cell death inhibition by Hsp70, by its targeting of both upstream and downstream mitochondrial processes, while the precise mechanisms by which it interferes with the activation of caspase-9 remains to be clarified.

In conclusion, ibuprofen potentiated the antitumoural properties of cisplatin in the cells of lung adenocarcinoma, via a mechanism of action mediated by the suppression of Hsp70. These findings may promote the development of a new strategy to increase the effectiveness of cisplatin in the treatment of NSCLCs, as well as highlight the putative merits of developing anticancer treatments targeting Hsp70.

## Materials and Methods

### Materials

The mouse monoclonal anti-Hsp70, the rat monoclonal anti-Hsc70 and rabbit polyclonal HSF-1 antibodies purchased from Stressgen – Enzo Life Sciences, Inc., Plymouth Meeting, PA, USA. Anti-Bax rabbit polyclonal (N-20) and anti-VDAC-1 goat polyclonal (N-18) antibodies were purchased from Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA. Anti-cytochrome c mouse monoclonal antibody (S56433) was obtained from BD Pharmingen Inc., San Diego, CA, USA. Anti-caspase 9 and -ERK antibodies were acquired from Cell Signaling Technology Inc., Danvers, MA, USA. The mouse monoclonal antibody against actin was obtained from Chemicon International Inc., Temecula, CA, USA. Anti-Bax 647 monoclonal antibody and other reagents were purchased from Sigma-Aldrich, St. Louis, MO, USA.

### Cell culture and viability assay

A549 and H358 lung cancer cell lines were cultured in Dulbecco’s modified Eagle’s medium containing 10% foetal bovine serum at 37°C. BEAS-2B cells were grown in bronchial epithelial basal medium. All NSAID and cisplatin were dissolved in dimethyl sulphoxide and added to the medium at indicated concentrations. The activity of mitochondrial dehydrogenase 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to measure cell death/survival. The reaction product was measured at A\textsubscript{570}, and the relative viability of cells treated with reagents versus untreated cells was calculated.

### TUNEL staining

The TUNEL assay was performed using an in situ cell death detection kit (F Hoffmann-La Roche, Basel, Switzerland) according to the manufacturer’s instructions. The ratio of TUNEL-positive cells to the total number of cells was calculated.

### Immunoprecipitation and cell fractionation

A549 cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM sodium orthovanadate, 1 mM EDTA, 0.1%, NP-40, 10 mM NaF) containing the Calbiochem Protease Inhibitor Cocktail Set III (Merck KGaA, Darmstadt, Germany). The cell lysates and immunoprecipitates were resolved in Laemmli sample buffer. The samples underwent sodium dodecyl sulphate-polyacrylamide gel electrophoresis were transferred to a polyvinylidene difluoride membrane, reacted with the respective antibodies, and detected with an ECL chemiluminescence detection kit (GE Healthcare, Fairfield, CT, USA). For the immunoprecipitation, the cell lysates were
incubated with the indicated antibodies for 1 h at 4 °C. Protein G- Sepharose beads were added to collect the immunocomplexes for an additional 1 h of incubation. The pellets were washed three times with lysis buffer. The mitochondria and cytosol fractions were prepared as described previously.46

Chromatin immunoprecipitation (ChIP) assay. ChIP assays were performed as described previously,46 using an EZ ChIP kit (Upstate Biotechnology Inc., Waltham, MA, USA). Briefly, after adding formaldehyde, A549 cells were suspended in SDS lysis buffer and the chromatin DNA was disrupted by sonication. For the immunoprecipitation, the lysate was incubated with anti-HSF-1 antibody, followed by immobilization on salmon sperm DNA/Gel protein G agarose. The protein/DNA complexes extracted with elution buffer were heated to 65 °C for 6 h to reverse cross-links, then digested with proteasome K. DNA fragments were amplified in PCR with the ChIP assay primers containing the heat shock element sites in human Hsp70 promoter. PCR primers for the ChIP assay were as follows: Hsp70(−103)−7 (F), 5′-TGATGGTGGTGGGAGGAGGCT-3′ and (R) 5′-AAAAGGTAGTGGAGCTGGC-3′.

Reverse transcriptase-PCR. RT-PCR was carried out using a Qiagen (Valencia, CA, USA) One-Step RT-PCR Kit. We used the following primer pairs to amplify: Hsp70, (F) 5′-ATGAAAGCTGCTTCACTCTCA-3′, (R) 5′-ACACCCAACAGAAGATGCAAT-3′; HSF-1, (F) 5′-TGGGACGCGGCGAGGTTT-3′; (R) 5′-AGGCGGTCCACCACTGAC-3′; actin, (F) 5′-AGGAGCATCCTACCGCT-GA-3′; (R) 5′-CATCTTTGCTGAGAATCCCA-3′. The products were examined by agarose gel electrophoresis after 24 cycles.

RNA interference. The sequences of the sense strands used to generate specific siRNA were obtained as follows: HSF-1, 5′-AACTACTTCAAGCCACAAAC AA-3′; 5′-AAGAAGTAAAGCATAAGATG-3′; 5′-AAGTGCCTGCAAACGCTT-3′. The siRNAs were synthesized using the Silencer siRNA construction kit (Ambion; Applied Biosystems Inc., Carlsbad, CA, USA). Double-stranded Hsp70 and control siRNA duplex were synthesized as followed by Qiagen: Hsp70-specific sequence, 5′-CCAUUGUGAGGGAGUUGUAUU-3′. A549 cells were transfected with each siRNA (10 nmol/l) using Lipofectamine 2000 (Invitrogen; Applied Biosystems Inc.), and grown for 72 h to allow an effective decrease in the expression of the respective target molecules.

Quantification of apoptosis by flow cytometry. A549 cells were washed with Annexin V staining buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2), and incubated with CF488A-Annexin V and 50 μM PI. Apoptotic cells were determined by flow cytometry (Keyence Corporation, Osaka, Japan) with the red excitation: 560 ± 20 nm band pass filter, detection: 535 ± 20 nm band pass filter, green excitation: 470 ± 40 nm band pass filter, detection: 535 ± 50 nm band pass filter) fluorescence channels. Flow cytometric analysis was assayed with the JC-1 Mitochondrial Membrane Potential Kit (AAT Bioquest, Sunnyvale, CA, USA) according to the manufacturer’s directions, using a FACScanCalibur, and the results were analyzed by CellQuest software.

In vitro caspase-9 activity determination. Caspase-9 activity was measured by a fluorometric assay in whole-cell lysates using Ac- Leu-Glu- His-Asp-MCA substrate (Peptide International Inc., Louisville, KY, USA). A549 cells were mixed with Ac-LEHD-MCA in ICE standard buffer (100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 10 mM DTT, 1 mM PMSF), and cleavage of the fluorogenic peptide substrate was monitored at 37 °C for 20 min by a SPECTRAmax GEMINI EM ( Molecular Device, Sunnyvale, CA, USA) fluorometer with excitation at 370 nm and emission at 480 nm.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This work was supported, in part, by a Grant-in-Aid (23591477) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

1. Tavaria M, Gabriele T, Kola I, Anderson RL. A hitchhiker’s guide to the human Hsp70 family. Cell Stress Chaperones 1996; 1: 23–28.
2. Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res 1999; 248: 35–43.
3. Aguiare, A, Phillips P, Dudeja V, Hashakand A, Shafar R, Dawra R et al. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreas adenocarcinoma. Cancer Res 2007; 67: 616–625.
4. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL. Heat shock protein hsp70 in patients with auxiliary lymph node-negative breast cancer. J Natl Cancer Inst 1993; 85: 1744–1747.
5. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000; 60: 7098–7105.
6. Vargas-Roig LM, Gago FE, Tello O, Amsellem S, Fishelson S, Bouscary D, Valensi F. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998; 79: 468–475.
7. Igney FH, Krammer PH. Death and anti-death: tumor resistance to apoptosis. Nat Rev Cancer 2002; 2: 277–288.
8. Gabai VL, Merlin AB, Mosser DD, Cannon AW, Rits S, Shrifin V et al. Hsp70 prevents activations of stress genes. A novel pathway of cellular thermotolerance. J Biol Chem 1997; 272: 18003–18037.
9. Merlin AB, Yanglom JA, Gabai VL, Zon L, Ganiatsas S, Moss D et al. Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by Hsp 72. Mol Cell Biol 1999; 19: 2547–2553.
10. Park HS, Cho SG, Kim G, Hwang HS, Noh KH, Kim MS et al. Heat shock protein hsp72 is a negative regulator of apoptosis signal-regulating kinase 1. Mol Cell Biol 2002; 22: 7721–7730.
11. Mosser DD, Morimoto RI. Molecular chaperones and the stress of onogenesis. Oncogene 2004; 23: 2907–2918.
12. Behe HM, Wolf BB, Cahn K, Mosser DD, Mahboubi A, Kuwana T et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2: 469–475.
13. Saleh A, Sinivasan SA, Bakir L, Robbins PD, Alnemri ES. Negative regulation of the death pathway controlled by Hsp72. Cell Struct Funct 1997; 22: 38729–38739.
14. Zermati Y, Garrido C, Amsellem S, Fishelson S, Bouscary D, Valensi F et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med 2001; 193: 247–254.
15. Schmitt E, Gehrmann M, Brunet M, Muthoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leuk Biol 2007; 81: 15–27.
16. Gotch T, Terada K, Oyadomari S, Mori M. Hsp70-Dnaj chaperone pair prevents nitric oxide- and CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria. Cell Death Differ 2004; 11: 390–402.
17. Starkiewicz AP, Lachapelle G, Foo CZ, Radiom SM, Mosser DD. Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing Bax translocation. J Biol Chem 2005; 280: 38729–38739.
18. Hosokawa N, Hirayoshi K, Nakai A, Hosokawa Y, Masui N, Yoshida M et al. Flavonoids inhibit the expression of heat shock proteins. Cell Struct Funct 1999; 15: 393–401.
19. Yokota S, Kikahara M, Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res 2000; 60: 2942–2948.
20. Westerheide SD, Kawahara TL, Orton K, Morimoto RI. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006; 281: 8161–8162.
21. Aghdassi A, Phillips P, Dudeja V, Davlahkandi D, Shafar R, Dawra R et al. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res 2007; 67: 816–825.
22. Phillips PA, Dudeja V, McCarron JA, Boja-Cacho D, Dawra RK, Grizzle WE et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 2007; 67: 9407–9416.
23. Giardello FM, Offerhaus GJ, DuBois RN. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 1995; 31A: 1071–1076.
24. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252–266.
25. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39: 1–20.
26. Shiff SJ, Koutsos MI, Oiao L, Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179–188.

27. Klampfer L, Cammenga J, Winiwarter HG, Nimer SD. Sodium salicylate activates caspases and induces apoptosis of myeloid leukemia cell lines. Blood 1999; 93: 2389–2394.

28. Shiff SJ, Oiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96: 491–503.

29. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC et al. Effect of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005; 11: 1618–1628.

30. Zhang L, Yu J, Park BH, Kintzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290: 899–902.

31. Liu JY, Ghezani D, Yeh S, Wu KK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3c. Cancer Res 2007; 67: 3185–3191.

32. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7285–7297.

33. Cho HJ, Ghezani D, Yeh S, Wu KK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3c. Cancer Res 2007; 67: 3185–3191.

34. Bonay M, Soler P, Riquet M, Battesti JP, Hance AJ, Tazi A et al. Expression of heat shock protein 70 levels and lung cancer risk: a case-control study nested in a large cohort study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1733–1737.

35. Michils A, Redivo M, Zegers de Beyl V, de Maertelaer V, Jacobovitz D, Rocmans P et al. Expression of heat shock protein 70 and 27 in non-small cell lung cancer and its clinical significance. J Huazhong Univ Sci Technolog Med Sci 2006; 25: 693–695.

36. Huang Q, Zu Y, Fu X, Wu T. Expression of heat shock protein 70 and 27 in non-small cell lung cancer and its clinical significance. J Huazhong Univ Sci Technolog Med Sci 2006; 25: 693–695.

37. Suzuki K, Ito Y, Wakai K, Kawado M, Hashimoto S, Seki N et al. Serum heat shock protein 70 levels and lung cancer risk: a case-control study nested in a large cohort study. Shock protein 70 levels and lung cancer risk: a case-control study nested in a large cohort study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1733–1737.

38. Zimmermann M, Nickl S, Lambers C, Haesser S, Mitterbauer A, Hoetzenecker K et al. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: A multi-institutional case-control study. Clin Chim Acta 2012; 413: 1115–1120.

39. Singh U, Bonogam-Rudloff E, Westermark B. A DNA sequence directed mutual transcription regulation of HSF1 and NFκB involves novel heat sensitive protein interactions. PLoS One 2009; 4: e6050.

40. Guo F, Rocha K, Bai P, Pnanapal M, Fiskus W, Boyapalle S et al. Abrogation of heat shock protein 70 induction as a strategy to increase antitumor activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005; 65: 10536–10544.

41. Ren A, Yan G, You B, Sun J. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells. Cancer Res 2008; 68: 2226–2233.

42. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 2004; 12: 955–965.

43. Juergens RA, Brahim JR. Adjuvant treatment in non-small cell lung cancer: where are we now? J Natl Compr Canc Netw 2006; 4: 595–600.

44. Steel R, Doherty JP, Buzzard K, Clemons N, Hawkins CJ, Anderson RL. Hsp72 Inhibits Apoptosis Upstream of the Mitochondria and Not through Interactions with Apaf-1. J Biol Chem 2006; 279: 51490–51499.

45. Yano M, Nakamuta S, Shiota M, Endo H, Kido H. Gatekeeper role of 14-3-3 protein in the apoptotic response to anticancer agents. Oncology 2003; 64: 114–123.

46. Yano M, Nakamuta S, Shiota M, Endo H, Kido H. Gatekeeper role of 14-3-3 protein in the apoptotic response to anticancer agents. Oncology 2003; 64: 114–123.